ÂÜÀòÂÒÂ×

Elizabeth Yan Zhang, MBA, PhD has extensive work experience in the field of genetic analysis and cellular analysis. Elizabeth Yan is currently the CEO and founder of GeneGoCell Inc., where they manage a testing laboratory and oversees all day-to-day operations, including laboratory operations, sales and marketing, and personnel training. Prior to this, they worked as a Field Application Scientist at Thermo Fisher Scientific and a Scientist at Genoptix, a Novartis company. In their earlier career, they served as a Postdoc Fellow at the La Jolla Institute for Allergy and Immunology, conducting research on drug targeting for autoimmune and inflammatory diseases. Elizabeth Yan also completed their PhD in Microbiology at the University of Kansas Medical Center, focusing on the effects of adaptor protein Gads on cytotoxic T cell-mediated immunity. Before their PhD, they worked as a Teaching Assistant and conducted research on the pathogenic mechanisms of contact hypersensitivity at the University of South Carolina. Elizabeth Yan also served as an Assistant Engineer and lab manager at the National Key Lab of Pharmaceutical Biotechnology in China, where they managed a lab and conducted research on the immune mechanism of severe acute respiratory syndrome.

Elizabeth Yan Zhang has a Bachelor's degree in Biological Sciences from Nanjing Normal University, China which they obtained from 1999 to 2003. Elizabeth Yan then pursued further education and received a PhD in Microbiology and Immunology from the University of Kansas Medical Center, where they studied from 2007 to 2011. Elizabeth also attended the University of South Carolina as a PhD student in Pharmaceutical Sciences from 2005 to 2006. In 2018, they earned a Master of Business Administration (MBA) from the University of California, San Diego - Rady School of Management. Additionally, Elizabeth has obtained certifications as a Certified Manager of Quality/Organizational Excellence (CMQ/OE) from ASQ - World Headquarters in 2022 and as a Specialist in Cytometry (SCYM (ASCP)CM) from the American Society for Clinical Pathology in 2017.